First Midwest Bank Trust Division acquired a new stake in Nu Skin Enterprises, Inc. (NYSE:NUS) in the second quarter, HoldingsChannel reports. The institutional investor acquired 5,450 shares of the company’s stock, valued at approximately $269,000.
Several other hedge funds have also made changes to their positions in NUS. Quadrant Capital Group LLC raised its stake in shares of Nu Skin Enterprises by 823.3% in the 1st quarter. Quadrant Capital Group LLC now owns 554 shares of the company’s stock valued at $26,000 after buying an additional 494 shares in the last quarter. Meeder Asset Management Inc. acquired a new position in shares of Nu Skin Enterprises in the 1st quarter valued at $65,000. Investors Research Corp acquired a new position in shares of Nu Skin Enterprises in the 1st quarter valued at $73,000. Exane Derivatives acquired a new position in shares of Nu Skin Enterprises in the 2nd quarter valued at $82,000. Finally, Machina Capital S.A.S. acquired a new position in shares of Nu Skin Enterprises in the 2nd quarter valued at $84,000. Institutional investors own 77.20% of the company’s stock.
NUS has been the subject of a number of recent research reports. Deutsche Bank upgraded shares of Nu Skin Enterprises from a “hold” rating to a “buy” rating and set a $60.00 price objective for the company in a research note on Wednesday, May 1st. Bank of America restated an “underperform” rating and issued a $52.00 price objective (down previously from $57.00) on shares of Nu Skin Enterprises in a research note on Wednesday, June 19th. Jefferies Financial Group cut shares of Nu Skin Enterprises from a “buy” rating to a “hold” rating and set a $40.00 price objective for the company. in a research note on Wednesday, July 17th. Citigroup dropped their target price on shares of Nu Skin Enterprises from $86.00 to $52.00 and set a “buy” rating for the company in a research report on Thursday, July 18th. Finally, Zacks Investment Research upgraded shares of Nu Skin Enterprises from a “sell” rating to a “hold” rating in a research report on Friday, May 3rd. Three analysts have rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $55.63.
Nu Skin Enterprises (NYSE:NUS) last announced its earnings results on Tuesday, April 30th. The company reported $0.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.71 by $0.06. The business had revenue of $623.60 million during the quarter, compared to analysts’ expectations of $615.98 million. Nu Skin Enterprises had a net margin of 4.82% and a return on equity of 26.81%. The firm’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter last year, the company posted $0.79 EPS. On average, equities analysts predict that Nu Skin Enterprises, Inc. will post 3.27 EPS for the current year.
Nu Skin Enterprises Company Profile
Nu Skin Enterprises, Inc develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex category brands worldwide. It provides skin care systems, including ageLOC Me customized skin care systems, ageLOC Spa systems, and ageLOC LumiSpa skin treatment and cleansing devices; and Epoch products, as well as a range of other cosmetic and personal care products.
Further Reading: Cost of Equity For A Business, Investors
Want to see what other hedge funds are holding NUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nu Skin Enterprises, Inc. (NYSE:NUS).
Receive News & Ratings for Nu Skin Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.